Obsidian Posts Q3 Loss of $50.7M With $324.4M Cash and 67% ORR in Melanoma
OBX sits 30% above its 52-week low of $9.6.
Summary
Obsidian reported a $50.7 million third-quarter net loss and $324.4 million in cash and securities, enough to fund operations into the second half of 2028, alongside the 67% ORR melanoma data presented at SITC and a new board appointment.
Key Events · Earnings and Guidance · OBX
-
Q3 Loss Widened by Galera Charge
Net loss was $50.7 million, or $1.23 per basic and diluted share, for the three months ended September 30, 2026, including $15.1 million of acquired in-process R&D expense tied to the Galera transaction.
-
Cash Funds Operations Into 2H 2028
Cash, cash equivalents and marketable securities totaled $324.4 million at September 30, 2026, which the company expects to support planned operations into the second half of 2028.
-
Melanoma Data: 67% ORR, 8.3-Month PFS
In 15 patients treated at the recommended Phase 2 dose, amsoki-cel showed a 67% objective response rate (2 complete, 8 partial responses), median PFS of 8.3 months and median duration of response not reached at 14.3 months of follow-up.
-
Clean Pooled Safety Across 37 Patients
No dose-limiting toxicities, treatment-related mortality, ICANS or ICU transfers were reported, with one Grade 3 cytokine release syndrome event.
Analysis · OBX · Life Sciences
The balance sheet is the headline: $324.4 million of cash and securities at September 30 funds operations into the second half of 2028, covering the registration-enabling Agni-01 readout management now guides to by year-end 2027. That removes any near-term financing need for a clinical-stage company burning roughly $38 million a quarter in R&D and G&A. On the clinical side, the 67% ORR and 8.3-month median PFS are the same figures already reported from SITC, but the filing adds the pooled safety set of 37 patients with no DLTs, no ICANS and no treatment-related deaths—the part regulators will weigh alongside efficacy. The quarter's loss was widened by a $15.1 million acquired IPR&D charge from the Galera transaction, a one-time item rather than a change in operating burn.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OBX was trading at $12.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $770.9M. The 52-week trading range was $9.60 to $49.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.